Embecta (Nasdaq:EMBC) today entered the insulin patch pump market with a major regulatory milestone.

Our sister site, Drug Delivery Business News, reports that the company received FDA clearance for its proprietary disposable insulin delivery system. The system caters to both the type 1 and type 2 diabetes populations.

Clearance marks another regulatory milestone for patch pumps designed for the type 2 population, as Insulet received FDA clearance for its Omnipod 5 for type 2 last week.